医学
鲁索利替尼
糖皮质激素
耐火材料(行星科学)
寄主(生物学)
移植物抗宿主病
疾病
免疫学
内科学
生物
骨髓
遗传学
骨髓纤维化
天体生物学
作者
Robert Zeiser,Nicola Polverelli,Ron Ram,Shahrukh K. Hashmi,Ronjon Chakraverty,Jan Moritz Middeke,Maurizio Musso,Sebastian Giebel,Ant Uzay,Peter Langmuir,Norbert Hollaender,Maanasa Gowda,Tommaso Stefanelli,Stephanie J. Lee,Takanori Teshima,Franco Locatelli
标识
DOI:10.1056/nejmoa2033122
摘要
Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1–JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.
科研通智能强力驱动
Strongly Powered by AbleSci AI